MVCD2
MCID: MCR112
MIFTS: 42

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 57 73 29 13 6 39
End-Stage Renal Disease, Diabetic, Susceptibility to 57 6
Proliferative Diabetic Retinopathy 73 71
Diabetic Nephropathy 73 71
Mvcd2 57 73
Microvascular Complications of Diabetes, Susceptibility to, 2 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic 57
End-Stage Renal Disease, Diabetic 57
Diabetic End-Stage Renal Disease 73

Classifications:



External Ids:

OMIM® 57 612623
OMIM Phenotypic Series 57 PS603933
MeSH 44 D048909
UMLS 71 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as end-stage renal disease, diabetic, susceptibility to, is related to uremia and congestive heart failure. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Clopidogrel and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and retina.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 507)
# Related Disease Score Top Affiliating Genes
1 uremia 30.6 EPO ACE
2 congestive heart failure 30.3 EPO ACE
3 neuropathy 30.2 EPO ACE
4 vascular disease 30.0 EPO ACE
5 end stage renal disease 30.0 EPO ACE
6 ischemia 29.9 EPO ACE
7 renal hypertension 29.9 EPO ACE
8 sleep apnea 29.9 EPO ACE
9 kidney disease 29.9 EPO ACE
10 peripheral nervous system disease 29.8 EPO ACE
11 polycystic kidney disease 29.7 EPO ACE
12 chronic kidney disease 29.7 EPO ACE
13 diabetic neuropathy 29.7 EPO ACE
14 pure autonomic failure 29.7 EPO ACE
15 peripheral vascular disease 29.7 EPO ACE
16 pulmonary edema 29.7 EPO ACE
17 polyneuropathy 29.6 EPO ACE
18 deficiency anemia 29.5 EPO ACE
19 diabetic autonomic neuropathy 29.4 EPO ACE
20 microvascular complications of diabetes 5 11.8
21 microvascular complications of diabetes 3 11.6
22 background diabetic retinopathy 11.6
23 microvascular complications of diabetes 1 11.6
24 vitreoretinopathy, neovascular inflammatory 11.5
25 microvascular complications of diabetes 7 11.5
26 severe nonproliferative diabetic retinopathy 11.4
27 retinal detachment 11.2
28 renal fibrosis 11.0
29 macular retinal edema 11.0
30 macular holes 11.0
31 neovascular glaucoma 10.9
32 yemenite deaf-blind hypopigmentation syndrome 10.9
33 diabetic macular edema 10.9
34 glomerulonephritis 10.8
35 vitreoretinopathy 10.8
36 nephrotic syndrome 10.7
37 cataract 10.7
38 rubeosis iridis 10.7
39 intraocular pressure quantitative trait locus 10.6
40 diabetes mellitus 10.6
41 eye disease 10.6
42 type 2 diabetes mellitus 10.6
43 retinal disease 10.6
44 retinal ischemia 10.6
45 hypertension, essential 10.6
46 type 1 diabetes mellitus 10.6
47 iga glomerulonephritis 10.6
48 hyperglycemia 10.6
49 membranous nephropathy 10.5
50 retinal vascular disease 10.5

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM®:

612623 (Updated 05-Mar-2021)

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
2
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
3
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
6
Enalaprilat Approved Phase 4 76420-72-9 6917719
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
8
Losartan Approved Phase 4 114798-26-4 3961
9
Doxazosin Approved Phase 4 74191-85-8 3157
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Ramipril Approved Phase 4 87333-19-5 5362129
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Dipivefrin Approved Phase 4 52365-63-6 3105
14
Insulin glargine Approved Phase 4 160337-95-1
15
Insulin glulisine Approved Phase 4 207748-29-6
16
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
17
Nisoldipine Approved Phase 4 63675-72-9 4499
18
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
19
Probucol Approved, Investigational Phase 4 23288-49-5 4912
20
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
21
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
22
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
23
Indapamide Approved Phase 4 26807-65-8 3702
24
Atorvastatin Approved Phase 4 134523-00-5 60823
25
Amlodipine Approved Phase 4 88150-42-9 2162
26
Atenolol Approved Phase 4 29122-68-7 2249
27
Clonidine Approved Phase 4 4205-90-7 2803
28
carbamide peroxide Approved Phase 4 124-43-6
29
Insulin lispro Approved Phase 4 133107-64-9
30
Verapamil Approved Phase 4 52-53-9 2520
31
Trandolapril Approved Phase 4 87679-37-6 5484727
32
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
33
Saxagliptin Approved Phase 4 361442-04-8 11243969
34
Metformin Approved Phase 4 657-24-9 14219 4091
35
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
36
Captopril Approved Phase 4 62571-86-2 44093
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
39
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477
40
Ranibizumab Approved Phase 4 347396-82-1 459903
41
Bevacizumab Approved, Investigational Phase 4 216974-75-3
42
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
43
tannic acid Approved Phase 4 1401-55-4
44
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
45
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
46
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
47
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
48
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
49
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354

Interventional clinical trials:

(show top 50) (show all 407)
# Name Status NCT ID Phase Drugs
1 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
2 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
3 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
4 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
5 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
6 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
7 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
8 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
9 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
10 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
11 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
12 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
13 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
14 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
15 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
16 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
17 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
18 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
19 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
20 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
21 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
22 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
23 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
24 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
25 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
26 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
27 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
28 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
29 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
30 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
31 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
32 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
33 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
34 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
35 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
36 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
37 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
38 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
39 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
40 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
41 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
42 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
43 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
44 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
45 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
46 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
47 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
48 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
49 A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy Completed NCT04521049 Phase 4 Saxagliptin 5mg
50 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study Completed NCT00153023 Phase 4 Telmisartan;Valsartan

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 71 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29 EPO

Anatomical Context for Microvascular Complications of Diabetes 2

MalaCards organs/tissues related to Microvascular Complications of Diabetes 2:

40
Endothelial, Eye, Retina, Placenta, Kidney, Brain, Pancreas

Publications for Microvascular Complications of Diabetes 2

Articles related to Microvascular Complications of Diabetes 2:

(show top 50) (show all 4286)
# Title Authors PMID Year
1
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 61 57 6
18458324 2008
2
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. 57 61
16120858 2005
3
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 6
19221299 2009
4
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 6
15635071 2005
5
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 6
15531537 2004
6
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 6
15534175 2004
7
ACE1 polymorphism and progression of SARS. 6
15381116 2004
8
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 6
15277638 2004
9
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 6
15110771 2004
10
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 6
14872014 2004
11
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 6
14657821 2003
12
Phenotype modulators in myophosphorylase deficiency. 6
12666117 2003
13
Interdependent effect of angiotensin-converting enzyme and platelet-activating factor acetylhydrolase gene polymorphisms on the progression of immunoglobulin A nephropathy. 6
12220450 2002
14
Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. 6
11956052 2002
15
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. 6
11687636 2001
16
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. 6
10841123 2000
17
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population. 6
10643899 1999
18
A dominant relationship between the ACE D allele and serum ACE levels in a Ghanaian population. 6
10636736 1999
19
The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. 6
10099885 1999
20
Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. 6
9916793 1999
21
Elite endurance athletes and the ACE I allele--the role of genes in athletic performance. 6
9737775 1998
22
ACE I/D gene polymorphism: presence of the ACE D allele increases the risk of coronary artery disease in younger individuals. 6
9699903 1998
23
Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. 6
9259580 1997
24
D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. 6
9236417 1997
25
Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. 6
9120002 1997
26
Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. 6
8644984 1996
27
Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. 6
8541160 1995
28
Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. 6
8675669 1995
29
Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. 6
7593601 1995
30
Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. 6
7729604 1995
31
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. 6
7854377 1995
32
Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. 6
7909524 1994
33
Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. 6
8208911 1994
34
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. 6
8170965 1994
35
Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. 6
8314010 1994
36
Genetic associations with human longevity at the APOE and ACE loci. 6
8136829 1994
37
A potent genetic risk factor for restenosis. 6
8298638 1993
38
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and parental history of myocardial infarction. 6
8131300 1993
39
Insertion/deletion (I/D) polymorphism at the locus for angiotensin I-converting enzyme and myocardial infarction. 6
8131299 1993
40
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. 6
1328889 1992
41
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. 6
1386652 1992
42
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. 6
1319114 1992
43
PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). 6
1313972 1992
44
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. 6
1976655 1990
45
Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. 6
2849100 1988
46
Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. 6
2847529 1988
47
Neovascular glaucoma - A review. 61
33595466 2021
48
The Relationship between Choroidal Thickness and Intracellular Oxidised-reduced Glutathione and Extracellular Thiol-disulfide Homeostasis at Different Stages of Diabetic Retinopathy. 61
33103488 2021
49
VASCULAR COMPLEXITY ANALYSIS IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF DIABETIC RETINOPATHY. 61
32568980 2021
50
Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. 61
33345998 2021

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EPO NM_000799.3(EPO):c.-1306C>A SNV risk factor 16602 rs1617640 7:100317298-100317298 7:100719675-100719675
2 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382 Insertion risk factor 18061 17:61565892-61565893 17:63488531-63488532

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....